

AKEBIA COMPLIANCE			
CONNECTICUT DISCLOSURE INFORMATION			
Document Number: FRM 445	Effective: 1 October 2024	Version: 2.0	

AKEBIA THERAPEUTICS INC.

CONNECTICUT DISCLOSURE INFORMATION

I. PURPOSE

On June 27, 2023, Connecticut Governor Ned Lamont signed into law HB 6669, a bill that requires pharmaceutical manufacturers, like Akebia Therapeutics, Inc. (Akebia), to disclose certain information to Prescribers in the course of conducting business. Specifically, this information includes:

• The list price of prescription drugs manufactured.

This information is to be provided in writing to all Prescribers licensed in the state of Connecticut, that Akebia conducts business with.

II. WHOLESALE ACQUISITION COST

PRODUCT NAME	MANUFACTURER	NDC	PKG SIZE
Vafseo® (Vadadustat) 150mg	Akebia Therapeutics, Inc.	59922-0641-60	60
		WAC / PACK	\$1,278.00
		WAC / TAB	\$21.30
Vafseo® (Vadadustat) 300mg	Akebia Therapeutics, Inc.	59922-0642-01	60
		WAC / PACK	\$2,556.00
		WAC / TAB	\$42.60

CONNECTICUT DISCLOSURE Page 1 of 1